Diabetes and dementia are linked by amyloidogenic amylin signaling
Amyloidogenic human amylin has emerged as a potential link between type-2 diabetes and Alzheimer’s disease.
Pathological amylin signaling may connect peripheral metabolic stress with neurodegeneration.
Chronic amylin receptor–cAMP–protein kinase A signaling disrupts cerebral energy metabolism and proteostasis.
Experimental studies implicate amyloidogenic amylin in Alzheimer’s disease-related pathological pathways.
Lowering circulating amyloidogenic amylin mitigates Alzheimer’s disease-like pathology in preclinical models.
Selective modulation of pathogenic amylin signaling offers a new pharmacological strategy for Alzheimer’s disease.
https://www.cell.com/trends/pharmacological-sciences/fulltext/S0165-6147(26)00178-1
